 CARMIEL, Israel and BOSTON, Oct. 11, 2021 PRNewswire -- Protalix BioTherapeutics, Inc. NYSE American: PLX TASE: PLX, a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group Chiesi Group, today provided a regulatory update regarding pegunigalsidase alfa PRX102 for the proposed treatment of Fabry disease which included an announcement of the receipt of the official Type A End-of-Review meeting minutes from the U.S. Food and Drug Administration FDA regarding the Complete Response Letter CRL received for the PRX102 Biologics License Application BLA confirming a potential pathway for resubmission of a BLA for PRX102. 